HC Wainwright Reaffirms “Neutral” Rating for Hookipa Pharma (NASDAQ:HOOK)

HC Wainwright restated their neutral rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a report issued on Friday,Benzinga reports.

A number of other research analysts have also recently issued reports on HOOK. JMP Securities lowered their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, November 21st. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and lowered their target price for the company from $48.00 to $2.00 in a report on Friday, December 20th.

Hookipa Pharma Trading Up 15.6 %

Shares of Hookipa Pharma stock opened at $2.15 on Friday. The business has a fifty day simple moving average of $2.48 and a two-hundred day simple moving average of $4.11. The firm has a market capitalization of $25.92 million, a P/E ratio of -0.58 and a beta of 0.71. Hookipa Pharma has a 12 month low of $1.75 and a 12 month high of $10.50.

Institutional Trading of Hookipa Pharma

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC grew its holdings in shares of Hookipa Pharma by 38.4% during the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after buying an additional 83,800 shares during the last quarter. Ikarian Capital LLC purchased a new position in Hookipa Pharma in the 3rd quarter worth approximately $228,000. Finally, Acadian Asset Management LLC boosted its stake in Hookipa Pharma by 12.3% during the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares during the last quarter. 63.88% of the stock is currently owned by institutional investors.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.